Credo Diagnostics Biomedical Pte. Ltd

The Pandemic

Coronavirus Disease 2019 (COVID-19), an acute respiratory illness caused by infection with the SARS-CoV-2, was initially reported to WHO in Wuhan, China, on December 31, 2019. The SARS-CoV-2 can be transmitted from person to person through the nose, eyes, or mouth. Furthermore, symptoms of SARS-CoV-2 infection vary. It can be asymptomatic or cause mild illnesses, including a runny nose, sore throat, cough, and fever. However, in severe cases, it can lead to pneumonia, breathing difficulties, or death. To date, millions of people around the world have died from COVID-19.Coronavirus Disease 2019 (COVID-19), an acute respiratory illness caused by infection with the SARS-CoV-2, was initially reported to WHO in Wuhan, China, on December 31, 2019. The SARS-CoV-2 can be transmitted from person to person through the nose, eyes, or mouth. Furthermore, symptoms of SARS-CoV-2 infection vary. It can cause mild illnesses, including a runny nose, sore throat, cough, and fever. However, in severe cases, it can lead to pneumonia, breathing difficulties, or death.

The Need

As the world continues to combat COVID-19, SARS-CoV-2 testing keeps playing a crucial role in stopping the spread of the virus and future variants. Particularly, a rapid and accurate diagnostic test for SARS-CoV-2 detection at the Point-of-Care becomes essential and generally adopted to help healthcare professionals to make decisions on the spot.

The Solution

VitaPCR™ SARS-CoV-2 Gen 2 Assay based on the proprietary RT-PCR technology provides significantly faster testing results than any other laboratory-based methods with higher accuracy than conventional rapid testing. With less than a minute of hands-on time, the test allows the detection of SARS-CoV-2 in 20 minutes from sample to results. On top of that, the comprehensive results information, including Ct values and fluorescence curves, can help healthcare providers make precise decisions and offer proper treatments in a timely manner.

General Diagnostic Procedure

 

Intuitive Result Interpretation

Reference

1. Trigt RV, Neat J, Brouwer JL, Hays A, Westerhof H. Deploying a rapid point of care polymerase chain reaction test for SARS-CoV-2 in a clinical research unit to ensure healthy volunteer safety. Bioanalysis. 2021;10.4155/bio-2021-0079.

2. Musumeci A, Vinci M, L'Episcopo F, et al. Implementation of Sample Pooling Procedure Using a Rapid SARS-CoV-2 Diagnostic Real-Time PCR Test Performed Prior to Hospital Admission of People with Intellectual Disabilities. Int J Environ Res Public Health. 2021;18(17):9317.

3. Fournier PE, Edouard S, Wurtz N, et al. Contagion Management at the Méditerranée Infection University Hospital Institute. J Clin Med. 2021;10(12):2627.

4. Fitoussi, F., Dupont, R., Tonen-Wolyec, S., & Bélec, L. (2021). Performances of the VitaPCR™ SARS-CoV-2 Assay during the second wave of the COVID-19 epidemic in France. Journal of medical virology, 93(7), 4351–4357.

5. Fournier PE, Zandotti C, Ninove L, et al. Contribution of VitaPCR SARS-CoV-2 to the emergency diagnosis of COVID-19. J Clin Virol. 2020;133:104682.